Library
On this page you can find relevant researchs on drug-related health topics, including HIV, hepatitis C, drug and overdose prevention, harm reduction and drug treatment. You can also find our Clinical Guidelines.
Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders
This quick guide for clinicians provides succinct, easily accessible information to clinicians about the use of medications to help patients with substance use disorders (SUDs) deal with chronic noncancer pain (CNCP). The guide includes information on 1)patient assessment; 2)chronic pain management; 3)patients treated with opioids; and 4)treatment agreements.
This quick guide for clinicians provides succinct, easily accessible information to clinicians about the use of medications to help patients with substance use disorders (SUDs) deal with chronic noncancer pain (CNCP). The guide includes information on 1)patient assessment; 2)chronic pain management; 3)patients treated with opioids; and 4)treatment agreements.
Patterns and Trends of Amphetamine-Type Stimulants and Other Drugs: Challenges for Asia and the Pacific 2013
Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) Programme highlights the most current patterns and trends of amphetamine-type stimulants and other drugs of use in East and Southeast Asia and provides overviews for the neighbouring regions of South Asia and the Pacific Island States and Territories. From all 15 countries that contributed to this report, 13 countries reported methamphetamine as the primary or secondary drug of use.
Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) Programme highlights the most current patterns and trends of amphetamine-type stimulants and other drugs of use in East and Southeast Asia and provides overviews for the neighbouring regions of South Asia and the Pacific Island States and Territories. From all 15 countries that contributed to this report, 13 countries reported methamphetamine as the primary or secondary drug of use.
International AIDS Society News October 2013
IAS give an update on their current activities including the 2013 Kuala Lumpur conference and the upcoming conference in Melbourne 2014.
IAS give an update on their current activities including the 2013 Kuala Lumpur conference and the upcoming conference in Melbourne 2014.
HIV situation among people who inject drugs in Romania
Roundtable on the HIV situation among people who inject drugs in Romania, 19 November 2013, Bucharest
Roundtable on the HIV situation among people who inject drugs in Romania, 19 November 2013, Bucharest
When Storytelling Makes a Difference between Pain and Peace
An interview with Andrey Rokhanskiy the director of the Institute for Legal Research and Strategy, which advocates for palliative care and patients who use drugs in Kharkiv, Ukraine.
An interview with Andrey Rokhanskiy the director of the Institute for Legal Research and Strategy, which advocates for palliative care and patients who use drugs in Kharkiv, Ukraine.
Canadian MP Megan Leslie
Listen to a great speech from Canadian MP Meagan Leslie about safe injecting sites.
Listen to a great speech from Canadian MP Meagan Leslie about safe injecting sites.
Meeting report - HIV situation among people who inject drugs in Romania
3rd Meeting on detecting and responding to outbreaks of HIV among people who inject drugs: 18 November 2013, Bucharest
3rd Meeting on detecting and responding to outbreaks of HIV among people who inject drugs: 18 November 2013, Bucharest
Is research in substance abuse undervalued?
An editorial in Addiction states “substance abuse research is undervalued, because research costs are salient while the benefits to research are more diffuse and difficult to quantify. Because of the inherently low value that policy-makers and society place on substance abuse research, it is particularly important for researchers to articulate the benefits of their work.”
An editorial in Addiction states “substance abuse research is undervalued, because research costs are salient while the benefits to research are more diffuse and difficult to quantify. Because of the inherently low value that policy-makers and society place on substance abuse research, it is particularly important for researchers to articulate the benefits of their work.”
Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation
Robert K. Brooner et. al study states that “substance abuse treatment incorporating daily methadone and weekly counseling is generally effective in reducing the harmful consequences of opioid dependence disorder. Approximately half of treatment seeking opioid-dependent patients also have a comorbid psychiatric disorder. “ The study concludes ” On-site and integrated psychiatric and substance misuse services in a methadone treatment setting might improve psychiatric outcomes compared with off-site and non-integrated substance misuse and psychiatric care.”
Robert K. Brooner et. al study states that “substance abuse treatment incorporating daily methadone and weekly counseling is generally effective in reducing the harmful consequences of opioid dependence disorder. Approximately half of treatment seeking opioid-dependent patients also have a comorbid psychiatric disorder. “ The study concludes ” On-site and integrated psychiatric and substance misuse services in a methadone treatment setting might improve psychiatric outcomes compared with off-site and non-integrated substance misuse and psychiatric care.”
Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone
Richard N. Rosenthal et. al conducted a study to “evaluate the safety and efficacy of buprenorphine implants (BI) versus placebo implants (PI) for the treatment”. The buprenophine implantable was developed to address problems with adherence, diversion and non-medical use. They concluded “Compared with placebo, buprenorphine implants result in significantly less frequent opioid use and are non-inferior to sublingual buprenorphine/naloxone tablets.”
Richard N. Rosenthal et. al conducted a study to “evaluate the safety and efficacy of buprenorphine implants (BI) versus placebo implants (PI) for the treatment”. The buprenophine implantable was developed to address problems with adherence, diversion and non-medical use. They concluded “Compared with placebo, buprenorphine implants result in significantly less frequent opioid use and are non-inferior to sublingual buprenorphine/naloxone tablets.”
